Capo Therapeutics

Capo Therapeutics, is developing peptide and epitope vaccines against various neurological disorders, in particular Alzheimers Disease, Lewy Body Dementia, Traumatic Brain Injury, as well as Parkinsons Disease, and Huntington Disease.

Capo Therapeutics, was founded to commercialize the unique vaccine formulation and approach that may overcome historical problems with vaccines against the proteins which drive Alzheimers Disease. The vaccine formulation is based on discovery made by researchers at The Institute of Molecular Medicine in Huntington Beach, CA, in collaborators with the University of California at Irvine, Irvine, CA and at Flinders University in Adelaide, Australia.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://capotherapeutics.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
4093 Oceanside Boulevard Suite B,CA 092056
Oceanside
United States
Email
Contact Number
+1 760 295 7208

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In designing more effective vaccines, various B cell antigenic epitopes from ?-amyloid and tau proteins were fused to a universal vaccine platform (based on a string of Th foreign epitopes, called Multi-TEP) and was added with an inulin-based adjuvant. The result of this approach yielded very high therapeutic titers of anti-AB and anti-tau antibodies as well as inducing powerful cellular immune responses in animal models.